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Neuroblastoma is a relatively radiosensitive tumour, but
because of its tendency to early dissemination, local radio-
therapy alone is rarely curative. Biologically targeted radio-
therapy is an alternative therapeutic strategy which exploits
tissue specific differences to enable relatively selective delivery
of radionuclides to tumour deposits. One way of targeting
neuroblastoma utilises biochemical mechanisms which prefer-
entially accumulate catecholamines, their precursors and ana-
logues such as metaiodobenzyl guanidine (mIBG) (Smets et
al., 1989; Paffenholz et al., 1989). This approach has met
with some therapeutic success (Vofite et al., 1987) but its
optimal role in patient management has yet to be defined.
Clearly a laboratory model for further investigation of tar-
geted radiotherapy of neuroblastoma with mIBG would be
valuable.
The cytogenetic, immunological and molecular biological
properties of the human neuroblastoma cell line NB1-G have
been extensively studied (Carachi et al., 1987). The response
of this line to irradiation has been investigated in detail
(Wheldon et al., 1985, 1986, 1987). The ability of NB1-G to
grow as multicellular tumour spheroids has enabled its use as
an in vitro model of biologically targeted radiotherapy using
monoclonal antibodies (Walker et al., 1988), although these
do not penetrate the centre of spheroids as readily as mIBG
(Mairs et al., 1991). The aim of this study was to define the
pharmacokinetics of mIBG uptake and retention by NBI-G,
and to investigate their modification by other drugs.
Cells were seeded into sixwell plates at an initial density of
5 x 105 per well. They were cultured as monolayers for 3 or 4
days at 37°C in 5% CO2 in Eagle's Minimal Essential
Medium containing 25 mM Hepes buffer, 10% foetal calf
serum, 2 mM glutamine, penicillin/streptomycin (100 IU
ml-') and amphotericin B (2.5pgml-'). All media and sup-
plements were obtained from Gibco (Paisley, UK). '31I-mIBG
(specific activity 37-185 MBq mg' or >1110 MBq mg-')
was obtained from Amersham International (Little Chalfont,
UK) and other reagents were purchased from Sigma (Poole,
UK).
To measure the uptake of '3'I-mIBG by the cells under
experimental conditions,. the monolayers were washed twice
and radioactivity was extracted with two 0.5ml aliquots of
10% (w/v) trichloroacetic acid. The activity of the combined
extracts was counted in a sodium iodide crystal, gamma well
detector (Canberra Packard, Berkshire, UK). Uptake is
usually expressed as a percentage of the control value for
each experiment. To establish baselines, uptake at 37°C over
various times was measured as a function of mIBG concen-
tration. Uptake at 4°C was also measured to assess tempera-
ture dependence.
To determine their effect on mIBG uptake, various drugs
were preincubated with monolayers. Then the medium was
replaced with one containing both the drug at the same final
concentration and '31I-mIBG. After 2 h the medium was
removed and the radioactivity was extracted as described
above. The preincubation was usually for 30min, as this
period was shown to be adequate for maximal drug effect,
but longer was necessary for glucose-free medium to have an
effect. The percentage contribution of active transport to
total mIBG uptake was determined in this way using desme-
thylimipramine and ouabain. Having established that for
0.1 M mIBG the active uptake mechanism predominated,
and that uptake was maximal after about 2 h, these condi-
tions were used for subsequent experiments. The effects of
reserpine, verapamil and nifedipine on mIBG uptake were
similarly investigated. The energy dependency of uptake was
investigated in several ways. Either medium containing no
glucose or 2-deoxy-glucose in place of glucose was used, or
sodium dithionite (sodium hydrosulfite) was added to deplete
the medium of dissolved oxygen. The effect of excess nore-
pinephrine on '31I-mIBG incorporation was evaluated by
concomitant addition of the two drugs to NBI-G mono-
layers. The sodium dependency of uptake was investigated by
use of medium containing 125 mM lithium chloride in place
of sodium chloride.
In retention studies, the monolayers were washed twice
after incubation with '311-mIBG. Warm mIBG-free medium
with or without reserpine, verapamil or nifedipine was then
added and the activity remaining in the cells was measured at
various time intervals.
Comparison was made with two other neuroblastoma cell
lines, SK-N-SH (Biedler et al., 1973) and IMR-32 (Tumil-
owicz et al., 1970), SK-N-SH accumulates mIBG by the
specific active uptake-l mechanism (Buck et al., 1985; Smets
et al., 1989), whereas IMR-32 does not (Buck et al., 1985).
The concentration dependency of mIBG uptake by the
three lines following 2h incubations at 37°C, is shown in
Figure 1. Compared with the high affinity and saturability of
SK-N-SH uptake, IMR-32 demonstrated low level incorpora-
tion which increased linearly with increasing mIBG concen-
tration. Accumulation of mIBG by NBI-G was greater than
that of IMR-32 but less than that of SK-N-SH at all concen-
trations of the drug up to 2 itM. The rate of uptake of
0.1 M mIBG by NB1-G at 37°C is shown in Figure 2, and
also indicates the saturability of the mechanism. When incu-
bations were conducted at 4°C, uptake was negligible (Figure
3a).
Tricyclic antidepressants such as desmethylimipramine pre-
vent re-uptake of neurotransmitters by adrenergic neurones.
At a concentration of 1.51L M, 30 min preincubation with
desmethylimipramine reduced 0.1yI M mIBG uptake into
NBI-G cell monolayers to 17.4% of control values, indi-
cating that at this concentration most mIBG accumulation is
accomplished by an active process (Figure 3b).
Ouabain is a specific inhibitor of sodium-potassium-depen-
dent ATP-ase transport mechanisms. Preincubation of NBI-
G cells with 1 mM ouabain reduced the uptake of 0.1IL M
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Figure 1 Uptake of '3l-mIBG by neuroblastoma cell
monolayers as a function of concentration. Incubation time 2 h.
Means ± S.D. of three measurements. Upper curve: SK-N-SH;
middle curve: NBI-G; lower curve: IMR-32.
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Figure 2 The effect of time on uptake of 0.lLM mIBG by
NBl-G monolayers.
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Figure 3 Uptake of O.l1IM mIBG by NBl-G monolayers after
incubation for 2 h at 37°C compared with uptake following
incubation: a, at 4°C; b, with 1.51LM desmethylimipramine; c, with
ImM ouabain; d, with sodium-depleted medium; e, with 1.5 mM
sodium dithionite; f, with ImM norepinephrine.
mIBG to 22% (Figure 3c). As greater concentrations of
mIBG were used, the proportion of uptake blocked by
ouabain was reduced. This inverse relationship with mIBG
concentration indicates a decreasing contribution of the
active uptake component at increasing concentrations of
mIBG.
Use of sodium-free medium reduced uptake of 0.1;M
mIBG to 63% (Figure 3d). While the uptake of 0.1I1M
mIBG from both glucose-free medium, and medium contain-
ing 2-deoxy-glucose was not significantly different following
30 min preincubation, uptake was reduced to 54% with
glucose-free medium, and 46% with 2-deoxy-glucose when
the preincubation time was extended to 18 h. Use of 1.5 mM
sodium dithionite effectively abolished active uptake, reduc-
ing total uptake to only 17% of the control value (Figure
3e).
The incorporation of 0.1 -I M '311-mIBG into NB1-G mono-
layers was reduced to 21% of control values by 1 mM (i.e.
104-fold molar excess) L-norepinephrine (Figure 3f). This is
similar to the inhibitory effects of 1 mM ouabain and 1.51 M
desmethylimipramine on 0.1 LM mIBG uptake. Therefore
passive accumulation by NB1-G cells accounts for about
20% of total uptake of 0.1I M mIBG.
No modification of uptake of 0.1 LM mIBG by NB1-G
cells was seen in the presence of verapamil, nifedipine or
reserpine.
Retention of mIBG after uptake by NB1-G cells was
limited. Most of the accumulated radiopharmaceutical
quickly left the cells with only about 20% retained after 3 to
4 h (Figure 4). Reserpine had a short lived and modest effect
on mIBG retention. At 2 h, cells incubated with 10 L M
reserpine after uptake of mIBG retained 37% more than
controls incubated with medium alone. At longer times and
with lower concentrations of reserpine, the amounts retained
were comparable with controls. Similarly cells incubated with
20p M verapamil after uptake of mIBG retained 32% more
than controls. Again by 3 to 4 h, the retained amounts were
similar for both treated and control cells. Nifedipine at con-
centrations of 10-100;L M had no discernable effect on egress
of mIBG from NB1-G cells.
These results indicate that the human neuroblastoma cell
line NB1-G shows active uptake (uptake-i) of mIBG, similar
to that seen in adrenal medullary cells (Jaques et al., 1984),
phaeochromocytoma cells (Jaques et al., 1987) and in other
neuroblastoma lines (Smets et al., 1989; Paffenholz et al.,
1989). This process is saturable, and is temperature, sodium
and oxygen dependent. It can be blocked by specific
inhibitors of sodium-potassium-dependent ATP-ase transport
mechanisms such as ouabain and by monoamine reuptake
inhibitors such as desmethylimipramine. Catecholamines such
as norepinephrine which are taken up by the same pathway
will competitively block uptake if present in excess. At the
low concentrations of mIBG (<0.2 iL M) which exist in vivo
during imaging and therapy (Smets et al., 1991), the uptake-I
mechanism is predominant.
Since mIBG taken up in this way is rapidly lost from the
cells, any drug which modifies release may be therapeutically
useful. Blake et al., (1988) observed significantly increased
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Figure 4 Retention of mIBG in NBI-G cells following incuba-
tion with 0. I1M mIBG for 2 h at 37°C.
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retention of mIBG due to nifedipine in one of five patients
undergoing treatment for phaeochromocytoma. Although
nifedipine does not appear to affect mIBG kinetics in NB1-
G, our demonstration that verapamil prolongs mIBG reten-
tion in this cell line is worthy of further investigation,
although the concentrations used were in excess of the
plasma levels of about 1-2 IL M achieved in clinical practice.
The site of intracellular storage of mIBG in the neuroblas-
toma cell line SK-N-SH is thought to be predominantly
extravesicular (Smets et al., 1989). Our finding that reserpine,
which prevents catecholamine storage in neurosecretory
granules, does not promote loss of mIBG from NB1-G, is
compatible with the observation that the majority of mIBG
taken up by this line is stored in the mitochondria (Gaze et
al., 1991).
We conclude that NB1-G is a suitable cell line for in vitro
studies of the targeted radiotherapy of human neuroblastoma
with mIBG.
This work was supported by the Cancer Research Campaign, grant
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